HARTMANN: Positive business development continues in the first quarter of 2024 – Earnings forecast raised for current financial year


  • Sales revenues increase to EUR 599 million, organic sales growth of 3.3%
  • At EUR 69 million, adjusted EBITDA is above the figure of the previous year, which was burdened by high additional costs
  • The Transformation Program continues to make important contributions to earnings
  • Earnings forecast range for 2024 raised by EUR 10 million to between EUR 210 million and EUR 250 million

Heidenheim, 26 April 2024. Successful product launches and the acquisition of new customers, as well as the focused, continued implementation of the Transformation Program, had a positive impact on HARTMANN's business development in the first quarter of 2024. The Company was once again able to demonstrate its resilience in a difficult market environment with material costs remaining at a high level.

In the first three months of the 2024 financial year, the HARTMANN GROUP generated sales revenues of EUR 599 million. This corresponds to organic sales growth of 3.3% compared to the same period of the previous year. At EUR 69 million, adjusted EBITDA was above the previous year's figure (EUR 49.9 million), which was burdened by high additional costs.

Sales performance of the segments

The Wound Care segment achieved further growth in advanced wound care. In particular, HARTMANN recorded volume growth in silicone-coated wound dressings.

In the Incontinence Management segment, the ranges for incontinence pants and products for moderate and severe incontinence showed particularly positive development, especially in the nursing home business and direct patient care.

The Infection Management segment showed differing developments. The Risk Prevention division recorded a downward trend due to falling market prices for personal protective equipment. In contrast, the Disinfection division recorded sales growth in both surface and hand disinfection, supported by product launches. Both inpatient and outpatient care developed positively.

In the Group's Complementary Divisions segment, CMC achieved sales growth due to the successful conclusion of contracts. Business development at KOB declined slightly, as there were no special effects compared to the same period of the previous year. Kneipp benefited from positive effects in drugstores and food retail in Germany and Austria.

Outlook 2024

With the focused continuation of the Transformation Program, HARTMANN expects a further contribution to earnings of just under EUR 50 million in the financial year 2024 and further strengthening of the Company's competitiveness and resilience. Planned investments of around EUR 170 million will create the basis for growth and cost improvements in the coming years.

The HARTMANN GROUP continues to expect moderate organic sales growth for the financial year 2024 and raises the outlook range for adjusted EBITDA to EUR 210 to 250 million (previously: EUR 200 to 240 million).


The HARTMANN GROUP is one of the leading European providers of professional medical and care products and associated services. Every day, healthcare professionals and patients rely on HARTMANN brands in the segments of Incontinence Management (e.g. MoliCare®), Wound Care (e.g. Zetuvit®, Cosmopor®) and Infection Management (e. g. Sterillium®). This is expressed in our brand promise of “Helps. Cares. Protects.” HARTMANN generated sales of EUR 2.3 billion in the 2023 financial year. Founded in 1818, the Company sells its products and solutions in 130 countries around the world. For the future, the HARTMANN GROUP is currently implementing its strategic Transformation Program with its high-performance, customer-oriented and passionate team.

To learn more about the HARTMANN GROUP, visit www.corporate.hartmann.info.